Showing results (241-250 of 293) with videos related to

Sort By:
Pageof 30
Modern Rheumatology|December 15, 2021
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Postgraduate Medical Journal|July 24, 2012
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?Richard J Wakefield, Maria Antonietta D'Agostino, Esperanza Naredo, et al.
Annals of the Rheumatic Diseases|November 13, 2012
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementMonika M Schoels, Désirée van der Heijde, Ferdinand C Breedveld, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2017
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, et al.
RMD Open|October 18, 2024
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47Josef S Smolen, Jakub Trefler, Artur Racewicz, et al.
Arthritis Research & Therapy|September 15, 2021
The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patientsBianka Marklein, Madeleine Jenning, Zoltán Konthur, et al.
Annals of the Rheumatic Diseases|December 2, 2017
Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the jointBiljana Smiljanovic, Anna Radzikowska, Ewa Kuca-Warnawin, et al.
Annals of the Rheumatic Diseases|February 19, 2017
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritisGerd R Burmester, Iain B McInnes, Joel Kremer, et al.
Lancet (London, England)|August 25, 2004
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialMichael E Farkouh, Howard Kirshner, Robert A Harrington, et al.
Pageof 30